Prijeđi na sadržaj

Bromazin

Izvor: Wikipedija
(Preusmjereno sa stranice Bromodifenhidramin)
Bromazin
(IUPAC) ime
2-[(4-bromofenil)-fenilmetoksi]-N,N-dimetiletanamin
Klinički podaci
MedlinePlus a682065
Identifikatori
CAS broj 1808-12-4 1808-12-4
ATC kod R06AA01
PubChem[1][2] 2444
DrugBank DB01237
ChemSpider[3] 2350
UNII 202J683U97 DaY
ChEBI CHEBI:59177 DaY
ChEMBL[4] CHEMBL1201245 DaY
Hemijski podaci
Formula C17H20BrNO 
Mol. masa 334,251 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Bioraspoloživost visoka
Vezivanje za proteine plazme 96%
Metabolizam Uglavnom hepatički (CYP-posredovano), takođe renalno
Poluvreme eliminacije 1 do 4 sata
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Oralno

Bromazin (Ambrodil, bromodifenhidramin) je antihistaminik i antiholinergik. On je halogenovana forma difenhidramina i u mnogim pogledima je nešto jače dejstvo.[5][6]

Osobine

[uredi | uredi kod]
Osobina Vrednost
Broj akceptora vodonika 2
Broj donora vodonika 0
Broj rotacionih veza 6
Particioni koeficijent[7] (ALogP) 4,1
Rastvorljivost[8] (logS, log(mol/L)) -5,5
Polarna površina[9] (PSA, Å2) 12,5

Reference

[uredi | uredi kod]
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7. 
  6. Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0. 
  7. Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o. 
  8. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573. 
  9. Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286. 

Spoljašnje veze

[uredi | uredi kod]